SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s di ...
What connects these trends is not a detailed engagement with policy or ideology, but a desire to make the past feel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback